“This impressive achievement underscores Hesperos’ innovative Human-on-a-Chip organ system technology that provides drug and (other medical product) developers more informative results about their products, more quickly and at lower cost than conventional animal testing. This validation of our service offerings by recognized experts aligns well with FDA’s renewed focus on phasing out animal testing,”
-Christopher Long, PhD, Director of Automation and Engineering
Highlights
- Christopher Long, PhD, Hesperos’ Director of Automation and Engineering, presented Hesperos at the ACC.25 Future Hub Innovation Pitch Challenge
- Hesperos was selected as the winner from a pool of NHLBI-funded startups
- This achievement comes as the U.S. Food and Drug Administration has unveiled a roadmap to reduce animal testing by accelerating the adoption of New Approach Methodologies (NAMs), which includes organ-on-a-chip systems like Hesperos' Human-on-a-Chip® technology
